The Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Tekturna are greater than its risks for the treatment of essential hypertension.
Inimtervishoius kasutatavate ravimite komitee jõudis otsusele, et Tekturnai kasulikkus essentsiaalse hüpertensiooni ravis on suurem kui sellega kaasnevad riskid.